Physiologic Functions and Therapeutic Applications of α7 Nicotinic Acetylcholine Receptor in Brain Disorders
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
Accumulating data suggest that α7 nicotinic acetylcholine receptors (α7nAChRs) are an important therapeutic target for the treatment of Alzheimer’s disease (AD) and schizophrenia. The homopentameric ligand-gated ion channel α7nAChR consists of five identical α7 subunits that are encoded by the CHRNA7 (cholinergic receptor nicotinic alpha7 subunit) gene. Moreover, α7nAChRs are densely distributed throughout the hippocampus, cortex, and thalamus brain regions, but sparsely in the striatum, forebrain, and medulla. Compared with other nAChRs, α7nAChR binds with low affinity to the naturally occurring neurotransmitter acetylcholine and the non-specific exogenous agonist nicotine, and with high affinity to the specific antagonists α-bungarotoxin and methyllycaconitine. Reports indicate that α7nAChR plays important roles in neurotransmitter release, cognitive functioning, and the cholinergic anti-inflammatory response. Genetic variations that alter CHRNA7 mRNA and protein expression or cause α7nAChR dysfunction are associated with many brain disorders. Our previous studies revealed that α7nAChR exerts neuroprotection in AD by acting as a cargo receptor for binding the autophagosomal marker protein LC3 and engulfing extracellular neurotoxic Aβ1–42 during autophagic degradation of the α7nAChR-Aβ1–42 complex. However, the role of α7nAChRs in other diseases remains unknown. Here, we review and summarize the essential characteristics and current findings concerning α7nAChRs in four common brain diseases (AD, Parkinson’s disease, schizophrenia, and depression), which may elucidate the role of α7nAChRs and inform innovative research and novel treatments that target α7nAChRs in brain disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The Trier Social Stress Test (TSST) is regarded as the gold standard in simulating a stressful social situation”
From Efficacy and safety of an alpha 7-nicotinic acetylcholine receptor agonist, VQW-765, in subjects with performance anxiety: randomised, double-blind, placebo-controlled trial (2025) · cites this paper as [13]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Feigin, V. L., Nichols, E., Alam, T., Bannick, M. S., Beghi, E., Blake, N., Culpepper, W. J., Dorsey, E. R., Elbaz, A., Ellenbogen, R. G., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30499-x · Cited by 5,644
Cui, C., Cui, J., Jin, F., Cui, Y., Li, R., Jiang, X., Tian, Y., Wang, K., Jiang, P., & Gao, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479571 · Cited by 5,203
Fagerberg, L., Hallström, B. M., Oksvold, P., Kampf, C., Djureinovic, D., Odeberg, J., Habuka, M., Tahmasebpoor, S., Danielsson, A., Edlund, K., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.035600 · Cited by 3,665
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565 · cited 1×
“Loss of cholinergic tone and acetylcholine levels in the brain are thought to be responsible for the gradual cognitive decline in AD patients [34].”
BackgroundNicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation
Wang, H., Yu, M., Ochani, M., Amella, C. A., Tanovic, M., Susarla, S., Li, J. H., Wang, H., Yang, H., Ulloa, L., et al. (2003) · Nature · doi:10.1038/nature01339 · Cited by 3,228 · cited 1×
“The expression of α7nAChRs in the immune system is of particular interest, as this system plays a crucial role in regulating the cholinergic anti-inflammatory pathway [13].”
Background2022 Alzheimer's disease facts and figures
(2022) · Alzheimer's & Dementia · doi:10.1002/alz.12638 · Cited by 2,341
The role of autophagy in neurodegenerative disease
Nixon, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3232 · Cited by 2,059
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus
Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., Polymeropoulos, M., Holik, J., Hopkins, J., Hoff, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.587 · Cited by 1,141 · cited 2×
“Inheritance of a defect in attentional disturbances in schizophrenia (a decrease in the normal inhibition of the P50 (50-millisecond latency) auditory-evoked response to the second of paired stimuli), is thought to be associated with DNA variants of the CHRNA7 gene [84].”
BackgroundA cholinergic-adrenergic hypothesis of mania and depression
Janowsky, D., Davis, J., El-Yousef, M. K., & Sekerke, H. J. (1972) · The Lancet · doi:10.1016/s0140-6736(72)93021-8 · Cited by 1,134
β-Amyloid1–42 Binds to α7 Nicotinic Acetylcholine Receptor with High Affinity
Wang, H.-Y., Lee, D. H. S., D'Andrea, M. R., Peterson, P. A., Shank, R. P., & Reitz, A. B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5626 · Cited by 822
Freedman, R., Hall, M., Adler, L. E., & Leonard, S. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00252-x · Cited by 678 · cited 3×
“Study evidence using [125I]-α-bungarotoxin to label α7nAChR expression on the cell surface has reported significantly fewer numbers of [125I]-α-bungarotoxin binding sites in the hippocampus in patients with schizophrenia compared with controls [28].”
BackgroundMethodInfluentialSchizophrenia: overview and treatment options.
(2014) · PubMed Central · Cited by 533
Nicotinic acetylcholine receptors: from structure to brain function
Hogg, R. C., Raggenbass, M., & Bertrand, D. (2003) · Reviews of Physiology, Biochemistry and Pharmacology · doi:10.1007/s10254-003-0005-1 · Cited by 528
Proof-of-Concept Trial of an α7 Nicotinic Agonist in Schizophrenia
Olincy, A., Harris, J. G., Johnson, L. L., Pender, V., Kongs, S., Allensworth, D., Ellis, J., Zerbe, G. O., Leonard, S., Stevens, K. E., et al. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.630 · Cited by 527
Nagele, R. G., D’Andrea, M. R., Anderson, W. J., & Wang, H.-Y. (2002) · Neuroscience · doi:10.1016/s0306-4522(01)00460-2 · Cited by 455
Leonard, S., Gault, J., Hopkins, J., Logel, J., Vianzon, R., Short, M., Drebing, C., Berger, R., Venn, D., Sirota, P., et al. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.12.1085 · Cited by 441
Wang, H., Lee, D. H. S., Davis, C. B., & Shank, R. P. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0751155.x · Cited by 435
Le Novere, N., & Changeux, J.-P. (1995) · Journal of Molecular Evolution · doi:10.1007/bf00167110 · Cited by 427
Initial phase 2 trial of a nicotinic agonist in schizophrenia
Freedman, R., Olincy, A., Buchanan, R. W., Harris, J. G., Gold, J. M., Johnson, L., Allensworth, D., Guzman-Bonilla, A., Clement, B., Ball, M. P., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071135 · Cited by 426
Mhyre, T. R., Boyd, J. T., Hamill, R. W., & Maguire-Zeiss, K. A. (2012) · Subcellular Biochemistry · doi:10.1007/978-94-007-5416-4_16 · Cited by 423
Drug candidates in clinical trials for Alzheimer’s disease
Hung, S.-Y., & Fu, W.-M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0355-7 · Cited by 420 · cited 8×
“The cholinesterase inhibitors donepezil, galantamine, and rivastigmine are first-line treatment options used to enhance brain acetylcholine levels in AD patients [32].”
BackgroundInfluentialSelf-citationSanders, A. R., Duan, J., Levinson, D. F., Shi, J., He, D., Hou, C., Burrell, G. J., Rice, J. P., Nertney, D. A., Olincy, A., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07101573 · Cited by 349
Levodopa for the Treatment of Parkinson's Disease
LeWitt, P. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmct0800326 · Cited by 312
Neuronal nicotinic acetylcholine receptor structure and function and response to nicotine
Dani, J. A. (2015) · International Review of Neurobiology · doi:10.1016/bs.irn.2015.07.001 · Cited by 309 · cited 3×
“In mammals, neuronal subunits of nAChRs are divided into α subunits (α2, α3, α4, α5, α6, α7, α9, and α10; α8 is cloned from the chicken brain) and β subunits (β2, β3, and β4) (Figure 1B) [6].”
BackgroundInfluentialThe Role of Genetics in the Etiology of Schizophrenia
Gejman, P. V., Sanders, A. R., & Duan, J. (2010) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.12.003 · Cited by 296
lynx1, an Endogenous Toxin-like Modulator of Nicotinic Acetylcholine Receptors in the Mammalian CNS
Miwa, J. M., Iban̆ez-Tallon, I., Crabtree, G. W., Sánchez, R., S̆ali, A., Role, L. W., & Heintz, N. (1999) · Neuron · doi:10.1016/s0896-6273(00)80757-6 · Cited by 292
Guan, Z.-Z., Zhang, X., Blennow, K., & Nordberg, A. (1999) · NeuroReport · doi:10.1097/00001756-199906030-00028 · Cited by 286
Guan, Z., Zhang, X., Ravid, R., & Nordberg, A. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0740237.x · Cited by 285
Thanvi, B., Lo, N., & Robinson, T. (2007) · Postgraduate Medical Journal · doi:10.1136/pgmj.2006.054759 · Cited by 281
Yu, W. H., Kumar, A., Peterhoff, C., Shapiro Kulnane, L., Uchiyama, Y., Lamb, B. T., Cuervo, A. M., & Nixon, R. A. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.05.010 · Cited by 279
Acetylcholine–dopamine balance hypothesis in the striatum: An update
Aosaki, T., Miura, M., Suzuki, T., Nishimura, K., & Masuda, M. (2010) · Geriatrics & Gerontology International · doi:10.1111/j.1447-0594.2010.00588.x · Cited by 274
Nicotinic receptors that bind α-bungarotoxin on neurons raise intracellular free ca2+
Vijayaraghavan, S., Pugh, P. C., Zhang, Z.-W., Rathouz, M. M., & Berg, D. K. (1992) · Neuron · doi:10.1016/0896-6273(92)90301-s · Cited by 264
Gault, J., Robinson, M., Berger, R., Drebing, C., Logel, J., Hopkins, J., Moore, T., Jacobs, S., Meriwether, J., Choi, M. J., et al. (1998) · Genomics · doi:10.1006/geno.1998.5363 · Cited by 245
The ‘magic’ of -dopa: why is it the gold standard Parkinson's disease therapy?
MERCURI, N., & BERNARDI, G. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.05.002 · Cited by 232
Kem, W. R. (2000) · Behavioural Brain Research · doi:10.1016/s0166-4328(00)00211-4 · Cited by 231
Hellström-Lindahl, E., Mousavi, M., Zhang, X., Ravid, R., & Nordberg, A. (1999) · Molecular Brain Research · doi:10.1016/s0169-328x(99)00030-3 · Cited by 215
Ibañez-Tallon, I., Miwa, J. M., Wang, H.-L., Adams, N. C., Crabtree, G. W., Sine, S. M., & Heintz, N. (2002) · Neuron · doi:10.1016/s0896-6273(02)00632-3 · Cited by 200 · cited 1×
“Lynx1 binds directly to α7nAChRs in mammalian HEK293T cells [27].”
BackgroundThe human CHRNA7 and CHRFAM7A genes: A review of the genetics, regulation, and function
Sinkus, M. L., Graw, S., Freedman, R., Ross, R. G., Lester, H. A., & Leonard, S. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.02.006 · Cited by 189
Autophagy protects neuron from Aβ-induced cytotoxicity
Hung, S.-Y., Huang, W.-P., Liou, H.-C., & Fu, W.-M. (2009) · Autophagy · doi:10.4161/auto.5.4.8096 · Cited by 181
Self-citationLieberman, J. A., Dunbar, G., Segreti, A. C., Girgis, R. R., Seoane, F., Beaver, J. S., Duan, N., & Hosford, D. A. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.259 · Cited by 175
Brain α7 Nicotinic Acetylcholine Receptor Assembly Requires NACHO
Gu, S., Matta, J. A., Lord, B., Harrington, A., Sutton, S. W., Davini, W. B., & Bredt, D. S. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.018 · Cited by 175
SWEET, R. D., & McDOWELL, F. H. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-83-4-456 · Cited by 172
Santos, M. D., Alkondon, M., Pereira Edna, F. R., Aracava, Y., Eisenberg, H. M., Maelicke, A., & Albuquerque, E. X. (2002) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12219-5 · Cited by 168
Corradi, J., & Bouzat, C. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.104240 · Cited by 167
Novel insights into muscarinic acetylcholine receptor function using gene targeting technology
Wess, J. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00195-0 · Cited by 166
Motor complications associated with chronic levodopa therapy in Parkinson's disease.
Obeso, J. A., Grandas, F., Vaamonde, J., Luquín, M. R., Artieda, J., Lera, G., Rodriguez, M. E., & Martínez‐Lage, J. M. (1989) · PubMed · Cited by 163
Mechanism of Action of Atypical Antipsychotic Drugs in Mood Disorders
Grinchii, D., & Dremencov, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249532 · Cited by 160
Williams, M. E., Burton, B., Urrutia, A., Shcherbatko, A., Chavez-Noriega, L. E., Cohen, C. J., & Aiyar, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410039200 · Cited by 152
Therapeutic Potential of α7 Nicotinic Acetylcholine Receptors
Bertrand, D., Lee, C., Flood, D. G., Marger, F., & Donnelly‐Roberts, D. L. (2015) · Pharmacological Reviews · doi:10.1124/pr.113.008581 · Cited by 150
Self-citationAraud, T., Graw, S. L., Berger, R., Lee, M., Neveu, E., Bertrand, D., & Leonard, S. S. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.06.018 · Cited by 136
Behavioral Tests in Neurotoxin-Induced Animal Models of Parkinson’s Disease
Prasad, E. M., & Hung, S. (2020) · Antioxidants · doi:10.3390/antiox9101007 · Cited by 136
Self-citationMortality in Schizophrenia-Spectrum Disorders: Recent Advances in Understanding and Management
Peritogiannis, V., Ninou, A., & Samakouri, M. A. (2022) · Healthcare · doi:10.3390/healthcare10122366 · Cited by 136
Alpha7 nicotinic receptors as therapeutic targets for Parkinson's disease
Quik, M., Zhang, D., McGregor, M. M., & Bordia, T. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.06.014 · Cited by 133
Host Cell‐Specific Folding and Assembly of the Neuronal Nicotinic Acetylcholine Receptor α7 Subunit
Cooper, S. T., & Millar, N. S. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68052140.x · Cited by 132
Psychiatric Manifestation in Patients with Parkinson's Disease
Han, J. W., Ahn, Y. D., Kim, W.-S., Shin, C. M., Jeong, S. J., Song, Y. S., Bae, Y. J., & Kim, J.-M. (2018) · Journal of Korean Medical Science · doi:10.3346/jkms.2018.33.e300 · Cited by 127
Celastrol Inhibits Dopaminergic Neuronal Death of Parkinson’s Disease through Activating Mitophagy
Lin, M., Lin, C., Chen, Y., Yang, H.-B., & Hung, S. (2019) · Antioxidants · doi:10.3390/antiox9010037 · Cited by 124
Self-citationCurrent Therapies in Clinical Trials of Parkinson’s Disease: A 2021 Update
Prasad, E. M., & Hung, S. (2021) · Pharmaceuticals · doi:10.3390/ph14080717 · Cited by 124
Self-citationSix Years of High-Level Levodopa Therapy in Severely Akinetic Parkinsonian Patients
Barbeau, A. (1976) · Archives of Neurology · doi:10.1001/archneur.1976.00500050019004 · Cited by 118
Toyohara, J., & Hashimoto, K. (2010) · The Open Medicinal Chemistry Journal · doi:10.2174/1874104501004010037 · Cited by 108
Han, B., Li, X., & Hao, J. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.04.002 · Cited by 108
Differential Regulation of α7 Nicotinic Receptor Gene (CHRNA7) Expression in Schizophrenic Smokers
Mexal, S., Berger, R., Logel, J., Ross, R. G., Freedman, R., & Leonard, S. (2010) · Journal of Molecular Neuroscience · doi:10.1007/s12031-009-9233-4 · Cited by 100
Postmortem stability of α-bungarotoxin binding sites in mouse and human brain
Davies, P., & Feisullin, S. (1981) · Brain Research · doi:10.1016/0006-8993(81)90148-7 · Cited by 100
Dajas‐Bailador, F., Heimala, K., & Wonnacott, S. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.5.1217 · Cited by 98
Walling, D., Marder, S. R., Kane, J., Fleischhacker, W. W., Keefe, R. S. E., Hosford, D. A., Dvergsten, C., Segreti, A. C., Beaver, J. S., Toler, S. M., et al. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv072 · Cited by 97
Zhao, D., Xu, X., Pan, L., Zhu, W., Fu, X., Guo, L., Lu, Q., & Wang, J. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-1007-2 · Cited by 86
The Duplicated α7 Subunits Assemble and Form Functional Nicotinic Receptors with the Full-length α7
Wang, Y., Xiao, C., Indersmitten, T., Freedman, R., Leonard, S., & Lester, H. A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.582858 · Cited by 85
α‐Bungarotoxin Binds to Low‐Affinity Nicotine Binding Sites in Rat Brain
Wonnacott, S. (1986) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1986.tb13078.x · Cited by 84
Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia
Wallace, T. L., & Bertrand, D. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.736498 · Cited by 77
Bordia, T., McGregor, M. M., Papke, R. L., Decker, M. W., McIntosh, J. M., & Quik, M. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.09.015 · Cited by 76
α7 Nicotinic ACh Receptors as a Ligand-Gated Source of Ca2+ Ions: The Search for a Ca2+ Optimum
Uteshev, V. V. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-2888-2_27 · Cited by 75
Mineur, Y. S., Mose, T. N., Blakeman, S., & Picciotto, M. R. (2018) · British Journal of Pharmacology · doi:10.1111/bph.13769 · Cited by 70
Stuckenholz, V., Bacher, M., Balzer‐Geldsetzer, M., Alvarez‐Fischer, D., Oertel, W. H., Dodel, R. C., & Noelker, C. (2013) · Journal of Parkinson s Disease · doi:10.3233/jpd-120157 · Cited by 64
Suzuki, S., Kawamata, J., Matsushita, T., Matsumura, A., Hisahara, S., Takata, K., Kitamura, Y., Kem, W. R., & Shimohama, S. (2012) · Journal of Neuroscience Research · doi:10.1002/jnr.23160 · Cited by 56
Distribution of α7 Nicotinic Acetylcholine Receptor Subunit mRNA in the Developing Mouse
Broide, R. S., Winzer‐Serhan, U. H., Chen, Y., & Leslie, F. M. (2019) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2019.00076 · Cited by 56
Qi, X., Nordberg, A. K., Xiu, J., & Guan, Z. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.04.002 · Cited by 54
Kantrowitz, J. T., Javitt, D. C., Freedman, R., Sehatpour, P., Kegeles, L. S., Carlson, M., Sobeih, T. M., Wall, M. M., Choo, T.-H. J., Vail, B., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0628-9 · Cited by 52
Thomsen, M. S., Weyn, A., & Mikkelsen, J. D. (2011) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00961.x · Cited by 47
Paolo, T. D., Grégoire, L., Feuerbach, D., Elbast, W., Weiss, H., & Gomez‐Mancilla, B. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.05.007 · Cited by 47
Chaperoning α7 neuronal nicotinic acetylcholine receptors
Vallés, A. S., & Barrantes, F. J. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2011.10.012 · Cited by 43
Recio-Barbero, M., Segarra, R., Zabala, A., González–Fraile, E., González-Pinto, A. M., & Ballesteros, J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.631589 · Cited by 43
Hung, S., Huang, W., Liou, H., & Fu, W. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.02.003 · Cited by 40
Self-citationGalantamine: Additional Benefits to Patients with Alzheimer’s Disease
Lilienfeld, S., & Parys, W. (2000) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051228 · Cited by 39
Zhang, D., McGregor, M. M., Decker, M. W., & Quik, M. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.216283 · Cited by 39
Lin, M., Chen, Y., Yang, H.-B., Lin, C., & Hung, S. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00803-7 · Cited by 30
Self-citationFitzgerald, P. J., Hale, P. J., Ghimire, A., & Watson, B. O. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2020.620119 · Cited by 30
α7 nicotinic receptor agonists reduce levodopa‐induced dyskinesias with severe nigrostriatal damage
Zhang, D., McGregor, M. M., Bordia, T., Perez, X. A., McIntosh, J. M., Decker, M. W., & Quik, M. (2015) · Movement Disorders · doi:10.1002/mds.26453 · Cited by 28
Mechanism of Action of Atypical Antipsychotic Drugs in Mood DisordersPreprint
Grinchii, D., & Dremencov, E. (2020) · Preprints.org · doi:10.20944/preprints202011.0143.v1 · Cited by 26
Javitt, D. C. (2014) · PubMed · Cited by 25
Paik, J., & Keam, S. J. (2018) · CNS Drugs · doi:10.1007/s40263-018-0552-2 · Cited by 20
Martín-Sánchez, C., Alés, E., Balseiro-Gómez, S., Atienza, G., Arnalich, F., Bordas, A., Cedillo, J. L., Rueda-Extremera, M., Chávez‐Reyes, A., & Montiel, C. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100341 · Cited by 18
Finlay-Schultz, J., Canastar, A., Short, M., Gazzar, M. E., Coughlan, C. M., & Leonard, S. S. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.276014 · Cited by 17
Davidson, M., Levi, L. W., Park, J., Nastas, I., Ford, L., Rassnick, S., Canuso, C. M., Davis, J. M., & Weiser, M. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.04.020 · Cited by 15
Peng, W., Mao, L., & Dang, X. (2022) · Gene · doi:10.1016/j.gene.2022.146777 · Cited by 14
Cited by
Abbas, K., Mustafa, M., Alam, M., Habib, S., Ahmad, W., Adnan, M., Hassan, M. I., & Usmani, N. (2025) · Neurogenetics · doi:10.1007/s10048-025-00821-y · Cited by 51
Angelova, V. T., GEORGIEV, B., Pencheva, T., Pajeva, I. K., Rangelov, M. A., Todorova, N. H., Zheleva‐Dimitrova, D., Kalcheva-Yovkova, E., Valkova, I., Vassilev, N. G., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16091194 · Cited by 35
Nagori, K., Pradhan, M., & Nakhate, K. T. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150925 · Cited by 27
Kumar, S., Akhila, P. V., & Suchiang, K. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.10.408 · Cited by 28
Advances in the discovery of heterocyclic-based drugs against Alzheimer’s disease
Sánchez, J. D., Alcántara, A. R., González, J. F., & Sánchez-Montero, J. M. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2264766 · Cited by 26
Metadata
- Authors
- Lee, C.-H., & Hung, S.-Y.
- Affiliations
- Kaohsiung Medical University (TW)
- China Medical University (TW)
- Corresponding author
- Hung, Shih-Ya
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-12-22
- Volume
- 15
- Issue
- 1
- Pages
- 31
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9865019
- OpenAlex
- W4312117327
- Cited by
- 50
- References
- 94
- Citations by year
- 2026: 12 · 2025: 21 · 2024: 12 · 2023: 5
- FWCI
- 0.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- the Ministry of Science and Technology of Taiwan (MOST 111-2320-B-039-044-MY3, MOST 110-2811-B-039-509, CMU109-S-28)
- China Medical University (MOST 111-2320-B-039-044-MY3, MOST 110-2811-B-039-509, CMU109-S-28)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- alpha7 nicotinic acetylcholine receptor, CHRNA7, Alzheimer's disease, schizophrenia, Parkinson's disease, depression, autophagy, amyloid-beta clearance, neuroprotection, neurotransmitter release, cognitive function, ligand-gated ion channels, alpha-bungarotoxin, methyllycaconitine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.